Status:
NOT_YET_RECRUITING
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Roxadustat has been approved for low-risk MDS clinical trials, but the trial results are not available. For refractory low-risk MDS, the effective rate of roxadustat treatment is about 20-30%, and rox...
Detailed Description
Patients with low-risk myelodysplastic syndrome who are refractory to the regular treatments have to live on transfusions which lead to poor quality of life (QoL) and survival. Roxadustat, an oral hyp...
Eligibility Criteria
Inclusion
- Low-risk MDS unresponsive to first-line therapy
Exclusion
- myelofibrosis
- Severe heart and kidney function bu'quan
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06020833
Start Date
August 1 2023
End Date
December 1 2026
Last Update
September 1 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.